Actively Recruiting
Evaluating Tislelizumab Plus Anlotinib as Consolidation Therapy After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer Patients Without Progression
Led by Yantai Yuhuangding Hospital · Updated on 2026-09-11
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining tislelizumab and anlotinib as a consolidation treatment for patients with limited-stage small cell lung cancer LS-SCLC who have not experienced disease progression after receiving concurrent or sequential chemoradiotherapy. This phase II, single-group study focuses on improving outcomes for this specific group of patients. Participants will receive tislelizumab at a dose of 200 mg on Day 1 along with anlotinib at 10 mg daily from Days 1 to 14 in each 3-week cycle. This combined treatment serves as consolidation therapy following the initial chemoradiotherapy. The study monitors patients up to 36 months for progression-free survival and 48 months for overall survival, with other measures like response rates and adverse events also assessed. Throughout the study, participants will undergo regular assessments to track disease status, treatment response, and safety. These evaluations include imaging and clinical tests according to established criteria. The study aims to measure progression-free survival and overall survival while closely monitoring any adverse effects related to the treatment over several years of follow-up.
CONDITIONS
Brief Title
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
Research Team
J
Jinbo Ma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here